"Retatrutide, a GIP, GLP-1, and glucagon receptor agonist for obesity: A phase 2 trial." New England Journal of Medicine , 389(6), 514-526
At the studys conclusion, researchers found that participants who took GLP-1 medications containing semaglutide or tirzepatide had a 41% decrease in their overall risk of developing an obesity-related cancer
Alkalinization of lysosomesas observed in v-ATPase-deficient modelhas been associated with swelling under certain physiological or cellular conditions to enhance their ability to perform critical functions
How many units of GHK-Cu do I draw
Whether you need guidance on managing medication-related weight gain, psychiatric treatment, or metabolic health, we provide expert, personalized care tailored to your unique needs
MTP: methylprednisolone